{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:11:30Z","timestamp":1777594290133,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contactlensjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contact Lens and Anterior Eye"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clae.2023.102097","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T02:50:42Z","timestamp":1702003842000},"page":"102097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of bilateral OC-01 (varenicline solution) nasal spray in alleviating signs and symptoms of dry eye disease: A systematic review"],"prefix":"10.1016","volume":"47","author":[{"given":"Antonio","family":"Ballesteros-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Borroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concepci\u00f3n","family":"De-Hita-Cantalejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Carmen","family":"S\u00e1nchez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serafin","family":"Sanchez-Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Rocha-de-Lossada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Mar\u00eda","family":"S\u00e1nchez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clae.2023.102097_b0005","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102097_b0010","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jtos.2017.03.006","article-title":"TFOS DEWS II tear film report","volume":"15","author":"Willcox","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102097_b0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jtos.2016.04.005","article-title":"Understanding symptoms and quality of life in patients with dry eye syndrome","volume":"14","author":"Barabino","year":"2016","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102097_b0020","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/ICO.0000000000002580","article-title":"Ocular discomfort and quality of life among patients in the dry eye assessment and management study","volume":"40","author":"Sayegh","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.clae.2023.102097_b0025","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102097_b0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1167\/iovs.64.7.19","article-title":"Autonomic nerve activity features according to dry eye type","volume":"64","author":"Kaido","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clae.2023.102097_b0035","doi-asserted-by":"crossref","first-page":"e0276945","DOI":"10.1371\/journal.pone.0276945","article-title":"Variability of autonomic nerve activity in dry eye with decreased tear stability","volume":"17","author":"Kaido","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.clae.2023.102097_b0040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/aos.13844","article-title":"Role of corneal nerves in ocular surface homeostasis and disease","volume":"97","author":"Labetoulle","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.clae.2023.102097_b0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.preteyeres.2009.04.003","article-title":"Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases","volume":"28","author":"Dartt","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.clae.2023.102097_b0050","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.2147\/OPTH.S284622","article-title":"Stimulating tear production: spotlight on neurostimulation","volume":"15","author":"Yu","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clae.2023.102097_b0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jtos.2018.11.002","article-title":"Neurostimulation in dry eye disease-past, present, and future","volume":"17","author":"Dieckmann","year":"2019","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102097_b0060","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s40265-022-01782-4","article-title":"Varenicline solution nasal spray: a review in dry eye disease","volume":"82","author":"Frampton","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.clae.2023.102097_b0065","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors","volume":"70","author":"Mihalak","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clae.2023.102097_b0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jtos.2022.05.001","article-title":"Nicotinic acetylcholine receptor stimulation: A new approach for stimulating tear secretion in dry eye disease","volume":"25","author":"Pflugfelder","year":"2022","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102097_b0075","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II pain and sensation report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102097_b0080","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/ICO.0000000000002941","article-title":"ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease","volume":"41","author":"Wirta","year":"2022","journal-title":"Cornea"},{"key":"10.1016\/j.clae.2023.102097_b0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtos.2021.12.007","article-title":"A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study","volume":"24","author":"Quiroz-Mercado","year":"2022","journal-title":"Ocular Surf"},{"key":"10.1016\/j.clae.2023.102097_b0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","article-title":"Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease The ONSET-2 Phase 3 Randomized Trial","volume":"129","author":"Wirta","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clae.2023.102097_b0095","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s40123-022-00530-x","article-title":"A Single Administration of OC-01 (Varenicline Solution) Nasal Spray Induces Short-Term Alterations in Conjunctival Goblet Cells in Patients with Dry Eye Disease","volume":"11","author":"Dieckmann","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.clae.2023.102097_b0100","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.clinthera.2022.09.013","article-title":"Bilateral Effect of OC-01 (Varenicline Solution) Nasal Spray for Treatment of Signs and Symptoms in Individuals with Mild, Moderate, and Severe Dry Eye Disease","volume":"44","author":"Katz","year":"2022","journal-title":"Clin Ther"},{"key":"10.1016\/j.clae.2023.102097_b0105","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40123-022-00607-7","article-title":"Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials","volume":"12","author":"Nijm","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.clae.2023.102097_b0110","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/OPX.0000000000001986","article-title":"Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?","volume":"100","author":"Sheppard","year":"2023","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.clae.2023.102097_b0115","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2147\/OPTH.S403953","article-title":"OC-01 (Varenicline Solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2","volume":"17","author":"Schallhorn","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clae.2023.102097_b0120","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews 2021:89.","DOI":"10.1136\/bmj.n71"},{"key":"10.1016\/j.clae.2023.102097_b0125","first-page":"372","article-title":"explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"2021","author":"Page","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.clae.2023.102097_b0130","unstructured":"DistillerSR. Version 2.35. DistillerSR Inc.; 2022. n.d. https:\/\/www.distillersr.com\/."},{"key":"10.1016\/j.clae.2023.102097_b0135","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II Diagnostic Methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102097_b0140","doi-asserted-by":"crossref","unstructured":"Tauber J, Berdy GJ, Wirta DL, Kr\u00f6sser S, Vittitow JL, GOBI Study Group. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study. Ophthalmology 2023;130:516\u201324. 10.1016\/j.ophtha.2022.12.021.","DOI":"10.1016\/j.ophtha.2022.12.021"},{"key":"10.1016\/j.clae.2023.102097_b0145","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/OPTH.S398843","article-title":"Validation of a Modified National Eye Institute Grading Scale for Corneal Fluorescein Staining","volume":"17","author":"Sall","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clae.2023.102097_b0150","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.clae.2023.102097_b0155","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. The","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clae.2023.102097_b0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.clae.2023.102097_b0170","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102097_b0195","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/DDDT.S207743","article-title":"An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease","volume":"14","author":"Tuan","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clae.2023.102097_b0230","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ophtha.2015.02.037","article-title":"Comparison of Two Questionnaires for Dry Eye Symptom Assessment: The Ocular Surface Disease Index and the Symptom Assessment in Dry Eye","volume":"122","author":"Amparo","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clae.2023.102097_b0235","article-title":"Correlation and Level of Agreement between the Ocular Surface Disease Index and the Symptom Assessment in Dry Eye Questionnaires: A Survey-Based Study","author":"Rodriguez-Garcia","year":"2023","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.clae.2023.102097_b0240","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jtos.2019.09.006","article-title":"Symptom improvement in dry eye subjects following intranasal tear neurostimulation: Results of two studies utilizing a controlled adverse environment","volume":"18","author":"Pattar","year":"2020","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102097_b0245","first-page":"478","article-title":"Comparison of the Schirmer I test with and without topical anesthesia for diagnosing dry eye","volume":"5","author":"Li","year":"2012","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.clae.2023.102097_b0250","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clae.2023.102097_b0255","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1136\/bjophthalmol-2015-306930","article-title":"Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up","volume":"100","author":"Straub","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clae.2023.102097_b0260","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clae.2023.102097_b0265","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clae.2023.102097_b0270","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clae.2023.102097_b0275","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1177\/11206721221088259","article-title":"Dry eye disease, a prominent manifestation of systemic autoimmune disorders","volume":"32","author":"Bustamante-Arias","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clae.2023.102097_b0280","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","article-title":"TFOS DEWS II iatrogenic report","volume":"15","author":"Gomes","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102097_b0285","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jtos.2017.04.001","article-title":"TFOS DEWS II Sex, Gender, and Hormones Report","volume":"15","author":"Sullivan","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102097_b0290","first-page":"1096","article-title":"Corneal staining after instillation of topical anesthetic (SSII)","volume":"29","author":"Josephson","year":"1988","journal-title":"Invest Ophthalmol vis Sci"},{"key":"10.1016\/j.clae.2023.102097_b0295","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.preteyeres.2018.11.007","article-title":"Reconsidering the central role of mucins in dry eye and ocular surface diseases","volume":"71","author":"Baudouin","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.clae.2023.102097_b0300","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jtos.2019.12.006","article-title":"Immune - Goblet cell interaction in the conjunctiva","volume":"18","author":"Alam","year":"2020","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102097_b0305","first-page":"2693","article-title":"Tear Total Lipid Concentration in Patients with Dry Eye Following Intranasal Neurostimulation","volume":"58","author":"Green","year":"2017","journal-title":"Invest Ophthalmol vis Sci"},{"key":"10.1016\/j.clae.2023.102097_b0310","first-page":"218","article-title":"On the sneeze-reflex and its control","volume":"45","author":"Hyd\u00e9n","year":"2007","journal-title":"Rhinology"},{"key":"10.1016\/j.clae.2023.102097_b0315","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1753465809340571","article-title":"Sneeze reflex: facts and fiction","volume":"3","author":"Songu","year":"2009","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.clae.2023.102097_b0320","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-023-03069-y","article-title":"The efficacy and safety of varenicline nasal spray for the management of dry eye signs: a systematic review and meta-analysis","volume":"23","author":"Bashrahil","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.clae.2023.102097_b0325","doi-asserted-by":"crossref","unstructured":"Barrientos RT, God\u00edn F, Rocha-De-Lossada C, Soifer M, S\u00e1nchez-Gonz\u00e1lez JM, Moreno-Toral E, et al. Ophthalmological Approach for the Diagnosis of Dry Eye Disease in Patients with Sj\u00f6gren\u2019s Syndrome. Life (Basel) 2022;12. 10.3390\/LIFE12111899.","DOI":"10.3390\/life12111899"},{"key":"10.1016\/j.clae.2023.102097_b0330","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.clinthera.2022.07.006","article-title":"Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial","volume":"44","author":"Torkildsen","year":"2022","journal-title":"Clin Ther"}],"container-title":["Contact Lens and Anterior Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367048423003387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367048423003387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T01:22:35Z","timestamp":1761268955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367048423003387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1367048423003387"],"URL":"https:\/\/doi.org\/10.1016\/j.clae.2023.102097","relation":{},"ISSN":["1367-0484"],"issn-type":[{"value":"1367-0484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of bilateral OC-01 (varenicline solution) nasal spray in alleviating signs and symptoms of dry eye disease: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Contact Lens and Anterior Eye","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clae.2023.102097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of British Contact Lens Association.","name":"copyright","label":"Copyright"}],"article-number":"102097"}}